Takashi Inozume

Chiba University — Japan

Medicine · Health Sciences

25h-index2.4kcitations232works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(127), Immune Cell Function and Interaction(76), CAR-T cell therapy research(67), Immunotherapy and Immune Responses(64), Cutaneous Melanoma Detection and Management(24)

Publications230 total

Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer
Nature Communications·2026Open Access
Identification of an extremely large-scale genomic rearrangement in the Mpox virus while retaining replicative capacity
Journal of General Virology·2026Open Access
A Case of Melanoma of the Glans With <scp> <i>BRAF</i> <sup>V600E</sup> </scp> Mutation Successfully Treated With Dabrafenib and Trametinib
The Journal of Dermatology·2026Open Access
Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens
Cell Reports·2025Open Access
Prognostic outcomes of immediate complete lymph node dissection versus observation in patients with acral melanoma of the sole with sentinel node metastasis: a retrospective, multicenter study
International Journal of Clinical Oncology·2025
Supplementary Figures from High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects
2025Open Access
Supplementary Tables from High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects
2025Open Access
Current Surgical Management for Acral Melanoma
Current Treatment Options in Oncology·2025· 1 citedOpen Access
Data from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Tables from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S9 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S7 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S10 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S8 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S2 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S1 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure 3 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S5 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
page 1 of 12Next →

Frequent Co-authors

Shinji Shimada(15), Naotaka Shibagaki(14), Tatsuyoshi Kawamura(13), Yukiko Kiniwa(10), Yasuhiro Nakamura(10), Satoshi Fukushima(10), Kazutoshi Harada(9), Naoya Yamazaki(9), Tatsuya Takenouchi(9), Yosuke Togashi(7), Kenjiro Namikawa(7), Shusuke Yoshikawa(7), Taiki Isei(7), Joji Nagasaki(6), Takehiro Ohnuma(6), Yoshiyasu Umeda(6), Masahito Kawazu(6), Osamu Yamasaki(6), Takeo Maekawa(6), Shigeto Matsushita(6)